Releases Details
Grant of Options
Released : March 05, 2019 07:00
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
|
Option Grants to PDMRs |
|
|
Doerfler, Doug |
390,200 |
|
Holtz, Ron |
177,600 |
|
Thompson, J. Stark |
26,900 |
|
Mandell, Art |
26,900 |
|
Erck, Stan |
26,900 |
|
Brooke, Will |
26,900 |
|
Johnston, John |
26,900 |
|
Douglas, Richard |
26,900 |
|
Total |
729,200 |
Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 04 March 2019, of
The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Names |
Doerfler, Doug Holtz, Ron Thompson, J. Stark Mandell, Art Erck, Stan Brooke, Will Johnston, John Douglas, Richard |
|
2 |
Reason for the notification |
|
|
a) |
Position/status
|
Doerfler, Doug - CEO and Director Holtz, Ron - CFO and Director Thompson, J. Stark - Non-executive Chairman Mandell, Art - Non-executive Director Erck, Stan - Non-executive Director Brooke, Will - Non-executive Director Johnston, John - Non-executive Director Douglas, Richard - Non-executive Director |
|
b) |
Initial notification /Amendment |
Initial Notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
MaxCyte, Inc. |
|
b) |
LEI |
54930053YHXULRFCU991 |
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a)
|
Description of the financial instrument, type of instrument |
Grant of Options over Shares of Common Stock |
|
b) |
Identification code |
US57777K1060 |
|
c) |
Nature of the transactions |
Grant of Options to PDMRs |
|
d)
|
Price(s) and volume(s) |
Doerfler, Doug - 390,200 at an exercise price of Holtz, Ron - 177,600 at an exercise price of Thompson, J. Stark - 26,900 at an exercise price of Mandell, Art - 26,900 at an exercise price of Erck, Stan - 26,900 at an exercise price of Brooke, Will - 26,900 at an exercise price of Johnston, John - 26,900 at an exercise price of Douglas, Richard - 26,900 at an exercise price of |
|
d)
|
Aggregated information - Aggregated volume - Price |
n/a |
|
e)
|
Date of the transactions |
04 March 2019 |
|
f) |
Place of the transaction |
Outside a trading venue |
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com
|
|
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
